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Abstract 
Spatial navigation is emerging as a critical factor in identifying preclinical Alzheimer’s disease (AD). 
However, the impact of inter-individual navigation ability and demographic risk factors (eg APOE, 
age, sex) on spatial navigation make it difficult to identify ‘at-high-risk’ of AD people in the 
preclinical stages. In the current study we use spatial navigation Big Data (n=27,108) from the Sea 
Hero Quest (SHQ) game to overcome these challenges by investigating whether Big Data can be used 
to benchmark a highly phenotyped healthy ageing lab cohort into high vs. low risk people based on 
their genetic (APOE) and demographic (sex, age, educational attainment) risk factors. Our results 
replicate previous findings in APOE ε4 carriers, indicative of grid-cell coding errors in the entorhinal 
cortex, the initial brain region affected by AD pathophysiology. We also show that although baseline 
navigation ability differs between men and women, sex does not interact with the APOE genotype to 
influence the manifestation of AD related spatial disturbance. Most importantly, we demonstrate that 
such high-risk preclinical cases can be reliably distinguished from low-risk participants using Big 
Data spatial navigation benchmarks. By contrast, participants were undistinguishable on 
neuropsychological episodic memory tests. Taken together, we present the first evidence to suggest 
that in the future, SHQ normative benchmark data can be used to more accurately classify spatial 
impairments in ‘at-high-risk’ of AD healthy participants at a more individual level, therefore 
providing the stepping stone for individualised diagnostics and outcome measures of cognitive 
symptoms in preclinical AD. 
 
 
Significance Statement 
We report that assessment of navigational behaviour using the Sea Hero Quest App provides a means 
of discriminating healthy ageing from genetically at-risk individuals of Alzheimer’s disease. It further 
highlights that the global Sea Hero Quest database can be employed as a normative benchmark data 
set to efficiently determine the significance of spatial abnormality suspected to be indicative of 
incipient AD on an individual level. 
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INTRODUCTION 
Spatial navigation is a promising cognitive fingerprint for underlying Alzheimer’s disease 
pathophysiology (1–8) and has been adopted by many high profile clinical trials (such as the the 
European Prevention of Alzheimer's Dementia Consortium) to improve the sensitivity of 
neurocognitive testing and assess the efficacy of potentially disease-modifying treatments. In fact, 
brain areas affected by AD pathophysiology in the preclinical stage (including the entorhinal cortex, 
posterior cingulate cortex, precuneus) form the key nodes in the spatial navigation network (6, 9–13). 
Recent evidence suggests that abnormal spatial navigation patterns may be present before episodic 
memory deficits, which are the current gold standard for AD diagnosis  (6, 14, 15).  
 
A major challenge at this stage, however, is to understand how inter-individual and demographic 
factors that affect spatial navigation in order to identify earliest pathological spatial navigation 
changes in AD (16–19). Understanding diversifying factors that influence variability in spatial ability 
in the healthy population and individuals at risk to develop AD will advance the diagnostic power of 
the spatial tests and support more personalised diagnostics and treatment approaches (17, 20–23). 
Among factors underlying navigation, age is a well-documented predictor of declining spatial 
abilities, as older adults show a strong bias toward egocentric rather than allocentric  strategies (24, 
25) leading to suboptimal navigation performance (26).  Age-related decline in allocentric process are 
due to changes in coding patterns of place, grid, border and head direction cells that underpin our 
ability to form cognitive maps of the environment and integrating environmental and self-motion cues 
to optimise navigational performance (27–29). However, decline in other cognitive domains such as 
general planning and cognitive control abilities(30) also contribute to spatial deficits in old age, 
suggesting that like most diagnostic tests, age-range normative cut-off scores are required (30, 31).  
Similarly, sex differences in navigation behaviour and underlying neuroanatomy have generated 
arguments for sex-specific clinicopathological AD phenotypes (17, 21, 32–35). Rodent models of the 
Morris Water Maze have shown that male rats consistently outperform females (36) and human 
studies display similar sex differences favouring males (37–40) across 57 countries in both map-
dependent allocentric and map-independent egocentric navigational strategies (27). Therefore, 
although spatial navigation tools must retain sensitivity and specificity to preclinical AD 
pathophysiology, it will be critical to develop diagnostic tools that can adjust for underlying sex 
differences.  
 
Finally, one of the biggest challenges in preclinical AD studies is to identify those who are at-high-
risk to develop symptomatic AD in the future. Genetic variation in the apolipoprotein E 4  allele 
carriers is currently the strongest known genetic risk factor for sporadic AD (7, 41–43). Compared to 
the ε3/ε3 carriers, those with the ε3ε4 show a three-four fold increased risk for AD (43, 44). 
Phenotypic characteristics of apoE e4 allele show that the cognitive profile of e4 carriers changes over 
the lifespan, with some cognitive advantage seen in young adulthood (39) and cognitive disturbances 
in mnemonic and spatial process in mid adulthood (45–47). Recent findings also show that temporal 
grid-cell like representation in the entorhinal cortex of apoE4 carriers are functionally unstable 
leading to a boundary-driven error correction during wayfinding (48). 
 
Taken together, there is increasing evidence that spatial deficits, in particular related to wayfinding, 
are present in preclinical AD long before episodic memory symptom emerge. However, at this stage it 
is very difficult to employ such knowledge on a clinical level, due to unknown inter-individual 
variability in navigation behaviour across people, which is vital for sensitive and specific diagnostics 
on an individual level. In the current study we address this issue by using Big Data (n=27,308) for 
navigation behaviour from the Sea Hero Quest App (49) to: i) determine whether we can replicate 
previous wayfinding affects in APOE ε3ε4 carriers compared to the Big Data; ii) to further 
disentangle inter-individual the effects of genetic risk for AD from the effects of sex, age and baseline 
cognition on spatial discrepancies; and iii) to explore whether AD specific spatial navigation changes 
can be detected on an individual level, when using the Big Data as benchmark comparison. We 
predicted that i) we would replicate previous APOE spatial navigation findings (7); ii) sex differences 
would make a significant impact on navigation behaviour; and iii) AD specific navigation changes 
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can be detected in an individual level when using the normative benchmark Big Data of Sea Hero 
Quest.  
  
RESULTS 
Background Characteristics and Neuropsychology 
In the lab-based cohort, the ε3ε3 and ε3ε4 groups did not differ in terms of their demographic 
characteristics (see supplementary Table 1) or their neuropsychological examination (Table 2). We 
examined the relationship between the three SHQ outcome variables (Fig. 1): Wayfinding distance 
travelled and wayfinding duration correlate (Pearson r = 0.61, p < 0.001); duration and flare accuracy 
correlate (r = −0.309, p < 0.001); but wayfinding distance travelled and flare accuracy are not 
correlated r = 0.04, p =.795); suggesting dissociable neural correlates that underlie performance, 
corroborating current notions that wayfinding distance relies more on grid-cell based navigational 
processes (51), and flare accuracy relies more on retrosplenial mediated processes (15). We consider 
wayfinding distance as the primary outcome measure (and the other outcomes are secondary) as early 
AD is characterised by abnormal changes in the grid cell code of the entorhinal cortex.  
 
Genotype effects on wayfinding  
There was a main effect of genotype (b=0.22; p=0.004; Fig. 2 A) on wayfinding distance, with ε3ε3 
carriers (M=3.79, SD=0.63) travelling a shorter distance during wayfinding relative to ε3ε4 carriers 
(M=4.45, SD=0.94) after controlling for age and sex. The mixed model for wayfinding duration (i.e. 
time taken to complete wayfinding levels) showed no main effect of genotype between ε3ε3 (M=4.66, 
SD=2.65) and ε3ε4 carriers (M=4.97, SD=1.36; Fig. 2 B). See Table 2 for group mean values and 
Table 3 for the effects of genotype on wayfinding distance and duration. Please refer to SI Appendix 
for results including a small high-risk ε4/ε4 carrier group, which showed an even larger effect for 
distance travelled (SI Appendix, Fig. S1).  
 
To further examine the different routes taken by the two genetic groups, we plotted the exact 
trajectory of each participant on wayfinding level 6, 8 and 11 using (x,y) coordinates generated during 
gameplay and found that ε3/ε4 carriers show a lower average distance to border than their ε3/ε3 
counterparts (Fig. 2 D-F). On level 6 and 8, ε3/ε4 carriers deviate from the shortest distance between 
the checkpoints and travel toward the border of the environment compared to the ε3ε3 carriers, who 
tend to navigate along the centre of the virtual environment. To check if the increase in wayfinding 
distance in ε3/ε4 carriers compared to the ε3/ε3 group was driven by any specific level, fixed effects 
linear models were fitted for level 6, 8 and 11 to test if the properties in one specific level captured 
this effect, or if this effect was an accumulative error over the three wayfinding levels. Using the 
same explanatory variables as in the final base model, the e4 allele was found to increase wayfinding 
distance on level 6 (F60=5.48, p=0.023) and level 8 (F60=4.08, p=0.04) but not on level 11 (see SI 
Appendix, Fig. S2; also see Fig. S5 for diagnostic plots underlying key assumptions of the linear 
mixed models).  
 
Genotype and sex effect on wayfinding  
No effects of sex were found on wayfinding distance as men (M=4.06, SD=0.87) and women 
(M=4.22, SD=0.91; b=0.02, p=0.12) took similarly efficient paths, but sex did affect duration taken to 
complete wayfinding levels, with men (M=4.33, SD=1.09) requiring less time to complete levels than 
women (M=5.26, SD=2.17; b=0.39, p=0.02; SI Appendix, Fig. S3(A)). Importantly, no interactive 
effects of genotype and sex on wayfinding distance or wayfinding duration were uncovered. 
 
Genotype and sex effects on path integration 
We then tested the effects of genotype and sex levels on flare accuracy, a measure of path integration.  
No main effect of genotype (b=0.04, p=0.14; Fig. 2 C) and no genotype*sex interactions were found. 
However, sex had a significant main effect on flare accuracy, with men (M=5.11, SD=1.3) scoring 
higher than women (M=4.31, SD=1.4; b=-0.36, p=0.04; SI Appendix, Fig. 3(B)).  
 
Memory and spatial navigation as predictors of APOE genotype  
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The sensitivity and specificity of a traditional memory task to predict APOE genotype compared to 
spatial navigation on SHQ was done using logistic regression and ROC curves. This was motivated by 
the prediction that memory deficits would not be detectable on current gold standard episodic memory 
tasks. Covarying for gender, non-verbal episodic memory (three-minute total recall score for the 
ROCF) and wayfinding distance in SHQ were used separate predictors in two logistic regression 
analyses. The regression model for wayfinding distance x2 (2) = 9.1, p=0.03, was statistically 
significant and correctly classified 71.3% of the APOE genotyped cohort (75%:ε3ε3 63.3%:ε3ε4). As 
predicted, the model for ROCF delayed recall was not significant x2 (2) = 9.1, p=0.393. An ROC 
curve was then computed showing both navigation and delayed recall as predictors of APOE 
genotype (Fig. 3). Consistent with the above, area under the curve values indicated that wayfinding 
distance (AUC .714, SE .068, 95% CI .555 - .822; pink curve), but not delayed recall (AUC .541, SE 
.074, 95% CI .286 - .578; gold curve) has a significant level of diagnostic accuracy.  
            
Benchmark data validates an effect of APOE4 on wayfinding. Having determined the diagnostic 
utility of SHQ for APOE genotype compared to standard memory test, we wanted to examine the 
utility of the population-level benchmark dataset as a normative control sample which could be used 
by clinicians in diagnostic settings. We took advantage of the fact that the benchmark SHQ dataset-as 
a representative of the population-predominantly includes ε3/ε3 carriers (75%) and performed a ROC 
curve with the ε3ε4 and the benchmark data as a representative of non-risk controls. Area under the 
curve values indicated a very similar significant level of diagnostic accuracy as was demonstrated 
with the lab only cohort (AUC .701 SE .031 95% CI .639 - .759; see Fig. 3 [dark pink curve]). 
Finally, to further representation the diagnostic utility of the benchmark population, we plotted each 
ε3ε4 carrier’s score over their age sex, education matched sub-population from the normal distribution 
of the UK population (see Fig. 4).  
 
DISCUSSION  
Our results show that i) we can replicate previous wayfinding changes in APOE gene carriers; ii) sex 
differences significantly impact on wayfinding behaviour but the effect of sex is negligible compared 
to APOE genetic risk; iii) healthy ‘at-genetic-risk’ of AD with no memory deficits can be 
distinguished on wayfinding measures on an individual level. 
   
In more detail, using navigation benchmark Big Data and smaller APOE genotyped cohorts, we show 
that adults ‘at-genetic-risk’ of AD with no clinically detectable cognitive deficits, not only navigate 
further during wayfinding, but show a bias in navigating towards the border of the virtual SHQ 
environment in large open areas. This supports the hypothesis that suboptimal navigation performance 
is present in preclinical AD and that this is detectable on levels of the SHQ game, even when a closely 
matched demographic sample is provided by the global SHQ data set. We also show that while sex 
accounts for variation in navigation performance, sex does not reduce the sensitivity of SHQ to 
discriminate healthy ageing from genetically at-risk individuals of Alzheimer’s disease. 
 
Although adults at-genetic risk of AD deviate from the shortest route (often the Euclidean between the 
checkpoints) towards the environmental border of the SHQ environment, they successfully completed 
the wayfinding levels albeit sub-optimally. Thus, we hypothesis that the navigational deficits detected 
here reflect an error corrective strategy (48) for which environmental boundaries hold valuable 
navigational cues that aid the navigators’ ability to self-localise and find their way through the 
environment when navigational uncertainty ensues. The neural substrates that give rise to the 
navigational uncertainty in the genetically at-risk group is most likely induced by errors in the grid 
cell system within the entorhinal cortex (see SI for further discussion). The entorhinal cortex is not 
only one of the first cites of AD pathology in the brain (13) but is also crucial for facilitating shortcut 
wayfinding behaviours and optimal navigation behaviour (56). Given that grid cells compute large-
scale information (30, 31) and encode representations of self-location by measuring distance travelled 
by the navigator (32, 33), it is not surprising grid cell dysfunction results in navigational discrepancies 
in at-risk individuals of AD.  
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Given that phenotypic heterogeneity currently reduces the diagnostic and prognostic power of 
neurocognitive evaluations for early AD, we also sought to investigate if demographic and 
neuropsychology diversity impact navigation. The effect of the genotype that was most prominent 
when the environmental space was large and open (level 6 and 8). In terms of sex, we did find strong 
evidence of better performance in males on baseline navigation ability but no evidence to suggest that 
males at-genetic-risk were less vulnerable (in the preclinical stage at least) to the effect of the APOE 
e4 genotype than women at-genetic-risk. In our opinion, this is a critical finding as it suggests that sex 
difference may not act on the phenotypic presentation of navigation deficits in the early asymptomatic 
stage of the disease. A recent meta-analysis (54) reports that women are particularly vulnerable to 
early underlying pathology between the ages of 55 and 70. Thus whether sex and genotype interact to 
predict navigational ability on SHQ in later preclinical or prodromal stages of AD remains to be 
investigated. In the interest of diagnostic sensitivity, the time at which an increased female 
susceptibility to underlying pathology manifests behaviourally is a high priority. Although we found a 
sex-independent navigational deficit in adults at genetic risk of AD, evidence for strong spatial 
disparities on navigation performance across the sexes globally (55) suggest that it is indeed 
appropriate to consider the need to stratify risk assessment by sex. For example, when genotype status 
is unknown, considering sex difference may hold prognostic value as many high profile previous 
studies already suggest (17, 21, 56).  
 
Based on data presented here on a population level and elsewhere, we now know that demographic 
diversity based on age, sex and nationality act on navigation proficiency, and men perform better at 
digital and real-life spatial navigation tasks  (57). This finding, coupled with a plethora of pre-existing 
evidence for natural age-related decline in spatial navigation (26), means that we must establish 
personalised normative measures to accurately assess spatial disturbances that have not been well-
established as a underlying feature in preclinical AD pathology. From a clinical standpoint, clinicians 
and researchers should be advised to consider not only age but also the sex of their putative patient 
before inferring pathological related spatial impairment. From a research perspective, researchers 
should work towards providing demographically corrected benchmarked scores for standardised 
neuropsychological test. To date, obtaining normative data of this nature has been challenged by 
heterogeneity in methodological approaches used to measure spatial navigation and uncertainty about 
population level differences in cognitive performance. Consistency across our non-risk control group 
and the benchmark scores is compelling evidence that SHQ may provide unique benchmarking data, 
on a global scale, by controlling for the demographical factors such as sex, advanced age and cultural 
background; factors which will alter how individuals perform on SHQ. Although level of education 
was included to refine the population data, education did not have a compelling effect on navigation 
performance in the global SHQ database. Further research is required to determine what demographic 
factors beyond age, sex and nationality will increase the sensitivity and specificity of navigation test 
for underlying preclinical AD.  
 
Despite illustrating for the first time the clinical utility of new epidemiological data gathered on a 
global scale using the SHQ game, our study has several limitations. Firstly, we focus on preclinical 
rather than symptomatic Alzheimer’s disease, seeking to evaluate the prognostic value of SHQ rather 
than validate SHQ data as a potential diagnostic tool. However, given that many excellent cognitive 
diagnostics measures exist for symptomatic AD, we question whether navigation measures have true 
utility in this aspect. Instead, identification of subtle cognitive preclinical changes will be of greater 
future importance to complement other biomarkers as diagnostic and treatment outcome measures. 
Secondly, only 47% of all ε3/ε4 carriers develop symptomatic AD. This is  consistent with about 50% 
of the ε3/ε4 individuals in this study being impaired relative to the demographically corrected 
benchmark L longitudinal studies are needed to truly determine how predictive spatial navigation 
combined with genotypic information is in the preclinical stages of the disease however. Further 
replication of our findings with preclinical cohorts defined by multiple cognitive, genetic and 
neurological markers is desirable, although it is promising that we replicate previous boundary 
findings (Kunz 2015). Moreover, although education was considered in the individualised approach to 
diagnosis of ‘at-risk’ AD, approx. 40% of the genotyped cohort has 15 years+ of education and 50% 
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of the cohort working in "professional" fields vs. skilled or low-skilled / manual, potentially leading to 
an over-representation at the educated individuals in this genotyped sample. Lastly, although best 
efforts were made to control for gaming proficiency, we cannot completely rule out a potential 
influence of previous gaming experience contributing to the observed male advantage in the data. 
Still, considering that we are investigating a 50-75 year old cohort, gaming proficiency should not 
play such a large role. More importantly, the difference of male and females in the SHQ data across 
ages does not change, suggesting that gaming proficiency plays only overall a minor role in assessing 
spatial navigation via an online App. 
 
In conclusion, our work supports the hypothesis that navigational discrepancies are present in 
preclinical AD and can be captured by Sea Hero Quest available on iOS and Android platforms.  We 
show for the first time promising evidence that normative data generated from the 3.7 million people 
who played SHQ worldwide, may in the future help us to create a prognostic test based on 
navigational proficiency – to help us to understand how the very earliest symptoms of AD is isolation 
of potentially confounding demographic factors such as sex, advancing age, educational attainment or 
cultural background. This should reduce the problematic nature of phenotype variation obscuring the 
assessment of spatial disorientation as a first symptom of AD and offer the promise of individually 
tailored solutions in healthcare settings. Thus, spatial navigation emerges as a promising cognitive 
fingerprint, which can complement existing biomarker for future AD diagnostics and disease 
intervention outcome measures. 
MATERIALS AND METHODS 
Participants 
APOE genotyped cohort. 
Between Feb, 2017 and June, 2017, 150 people between 50 to 75 years of age were recruited to 
participate in a research study at the University of East Anglia. All 150 participants were pre-screened 
for a history of psychiatric or neurological disease, history of substance dependence disorder or any 
significant relevant comorbidity. All participants had normal or corrected-to-normal vision. Family 
history of AD and history of antidepressant treatment with serotonin reuptake inhibitor (SSRI) drugs 
was retrospectivity obtained. Saliva samples were collected from those who passed this screening and 
apoE genotype status was determined.  
 
In total, 69 participants underwent cognitive testing. As just 23% of the population carry APOE ε3/ε4, 
all participants in our sample who tested positive for the ε3/ε4 allele completed cognitive testing. We 
selected a subset of the ε3/ε3 carriers that form the majority of the population (75%) to match the 
ε3/ε4 risk group for age and sex (see SI Appendix, Table S1 for group background characteristics). 
We did not include a third genetic subgroup of homozygous APOE-ε4carriers from the tested cohort, 
because they were too rare (n=5) although their scores are reported in the SI Appendix. E2 carriers 
were also excluded. 
During testing, three participants showed signs of distress and their data was excluded from 
subsequent analyses. One participant scored lower than 86 on the Addenbrooke’s Cognitive 
Examination and was classified as mildly cognitively impaired and excluded from the study. The final 
group sizes (post-exclusion) were: apoE ε3/ε3, n=29 and apoE ε3/ε4, n=31). Written consent was 
obtained from all participants and ethical approval was obtained from Faculty of Medicine and Health 
Sciences Ethics Committee at the University of East Anglia Reference FMH/2016/2017–11. 
 
The Benchmark Population.  
A unique population level benchmark dataset was generated by extracting a subset of the global Sea 
Hero Database (50) that matched the demographic profile of our lab-based genotype cohort, namely 
players from the UK aged 50-75 years old. Following extraction, 14,470 British men and 12,710 
British women (N = 27,108) remained as a representative normative sample of  heathy navigation 
performance on the basis that epidemiological studies have shown that the majority of the general 
population (~75%) are non-apoE4 carriers (36).  Participants from the benchmark sample were given 
the option to opt in or opt out of the data collection when they played the game on their personal 
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mobile phone, iPad or tablet. If a participants’ response was to opt in, their SHQ data was anonymised 
and stored securely by the T-Systems’ datacentre under the regulation of German data security law. 
Ethical approval was previously granted by Ethics Research Committee CPB/2013/015. *For more 
information on the global SHQ database see www.seaheroquest.com 
 
 
Outcome Measure 
Sea Hero Quest (SHQ)  
The SHQ app was developed in 2015 by our team and funded by Deutsche Telekom and Alzheimer’s 
Research UK. The app was created to be a reliable and valid measure of spatial navigation 
performance both in monitored research settings and unmonitored at-home settings (49). It was made 
available for free on the App Store and Play Store from May 2016 and since then over 4 million 
people have downloaded the App worldwide. The game performance is divided into two main 
domains: goal-oriented wayfinding and path integration. 
 
Goal-orientated wayfinding. In wayfinding levels, players initially see a map featuring a start location 
and several checkpoints to find in a set order, as illustrated in Fig 1. Checkpoints are buoys with flags 
marking the checkpoint number. Participants study a map of the level for a recorded number of 
seconds. When participants exit the map view, they are asked to immediately find the checkpoints (or 
goals) in the order indicated on the map under timed conditions.  As participants navigate the boat 
through the level, they must keep track of their location using self-motion and environmental 
landscape cues such as water-land separation. The initiation time is zero as the boat accelerates 
immediately after the map disappears. If the participant takes more than a set time, an arrow appears 
pointing in the direction along the Euclidean line to the goal to aid navigation. To familiarize 
themselves with the virtual environment and game controls, participants started with two easy 
learning levels 1 and 2. Wayfinding levels generate two measures of interest: 
- Wayfinding distance travelled to visit all required checkpoints is defined as the Wayfinding 
distance between all points recorded and is a proxy for navigation efficiency. To navigate 
efficiently, individuals need to form and retain a cognitive map of the environment (after 
viewing the map at the start of the level) and then consistently update self-location in that 
cognitive map based on the visual cues from the SHQ game.  
- Wayfinding duration, is defined as the time in seconds to complete a wayfinding level. 
While inefficient navigation also results in longer time to visit all checkpoints, increased 
duration is primarily due to the amount of acceleration that the player used. By “swiping up”, 
one can increase the speed of the boat temporarily, therefore reducing travel time but not 
changing the distance travelled at all. Since speeding up requires confidence in one’s sense of 
direction, the resulting wayfinding duration score we take duration as less representative of 
participants’ ability to navigate along the shortest path and more representative of non-
navigational factors such as confidence or the tendency to sample more cues before speeding 
up.  
 
Flare Accuracy. In path integration levels (in the game this is measured by flare accuracy on levels 9 
and 14), participants are not provided with an allocentric map. Instead, they immediately navigated 
along a river to find a flare gun. Once they find the flare gun at the end of the river , the boat rotates by 
180°, and participants are asked to choose one of three possible directions (right, front, left) that they 
believe points to the starting point. This level requires participants to a) form an accurate 
representation of the starting point relative to their position and b) integrate this representation with a 
representation of the direction they are facing after the rotation. (see Tu and colleagues for a similar 
path integration based experimental design(15)). In this case, gaming proficiency was not 
advantageous because participants simply view navigate a single passage and are then required to 
choose A,B,C direction as a single response. Depending on their accuracy, players receive either one, 
two or three stars. 
 
 
Procedure 
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Data collection 
Spatial navigation data was collected for both the APOE genotyped cohort and benchmark datasets 
using Sea Hero Quest, a digital game that we pre-designed to measure human navigation ability. 
Decisions on level selection was made by considering which levels had the most normative data and 
level type/difficulty (wayfinding or path integration). Level 1 and 2 were included for learning and 
practice navigating the boat, as well as normalising the data for App interaction with player 
proficiency. Level 3-5 were excluded as they did not challenge participants’ navigation skills and 
were intended to ease the players into the game. Further, starting with level 14, the sample size of the 
benchmark population drops substantially. This then left us with three wayfinding levels (6,8,11) and 
two path integration levels (9 and 14). Participants in the lab-based APOE cohorts provided their 
demographic information during a screening call and were then invited to the UEA to play SHQ. 
Participants from the benchmark population provided information regarding their sex, age, location 
and educational attainment (high-school, college, university) demographics in-app before playing 
SHQ  
 
 
APOE Genotyping   
DNA was collected using a Darcon tip buccal swab (Fisher Scientific, Leicestershire, United 
Kingdom, LE11 5RG). Buccal swabs were refrigerated at 2-4°C until DNA was extracted using the 
QAIGEN QIAamp DNA Mini Kit (QAIGEN, Manchester, United Kingdom, M15 6SH). DNA was 
quantified by analysing 2 μL aliquots of each extraction on a QUBIT 3.0 Fluorometer (Fisher 
Scientific, Leicestershire, United Kingdom, LE11 5RG). Successful DNA extractions were confirmed 
by the presence of a DNA concentration of 1.5μg or higher per 100μg AE buffer as indicated on the 
QUBIT reading. PCR amplification and plate read analysis was performed using Applied Biosystems 
7500 Fast Real-Time PCR System (Thermo Fisher Scientific, Ashford, United Kingdom, TN23 4FD). 
TaqMan Genotyping Master Mix was mixed with two single nucleotide polymorphisms of APOE 
(rs429358 at codon 112 and rs7412 at codon 158). These two single nucleotide polymorphisms 
determine the genotype of APOE2, Ε3, and Ε4 (Applied Biosystems, 2007).  
 
Statistical Analysis 
The data was analysed using SPSS (Version 23), RStudio (Version 1.0.153) and MATLAB (R2017a). 
Chi square and simple two tailed t-tests were used to test the significance of any demographic or 
neuropsychological differences between the genetic groups in our lab cohort. When quantifying the 
group differences, Cohen’s d was used as a measure of effect size. To control for the influence of 
player proficiency on digital devices, the SHQ data was pre-processed in MATLAB and participant 
performance on each level within the game was divided by the sum of the two practice levels: 
𝑙𝑒𝑣𝑒𝑙 𝑁 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 = ln( 
𝑙𝑒𝑣𝑒𝑙 𝑁
(𝑙𝑒𝑣𝑒𝑙 1 + 𝑙𝑒𝑣𝑒𝑙 2)
) 
To assess the fixed effects of genotype and sex, we first compared competing statistical models with 
the inclusion and exclusion of different demographic factors using the nlme package in R 
(https://cran.r-project.org/web/packages/nlme/index.html) that allows fitting fixed and random effects 
to evaluate the most appropriate model for data. In each model, subject-level random effects were 
included to vary the intercept for each subject and importantly to account for interdependence 
between repeated measures from playing multiple levels of the game. Three sets of linear models 
were fitted that included the following outcome variables: a) wayfinding distance and b) wayfinding 
duration, using scores from SHQ levels 6, 8 and 11 completed by each subject and c) flare accuracy 
on each of the two path integration levels (9 and 14). Model selection was based on relative goodness 
of fit and model simplicity (determined using gold standard Akaike and Bayesian information 
criterion, AIC and BIC, respectively).  
 
Age, sex and genotype, were retained as explanatory variables for the final model for each of the 
outcome variables. ACE defined by total score on the Addenbrooke’s Cognitive Examination-III 
screening tool (52), education, occupation, time spent on viewing the wayfinding maps (see Fig. 1 for 
maps) and non-verbal episodic memory (defined by 3minute delayed recall on Rey–Osterrieth 
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Complex Fig. Test; ROCF (53) ), were tested in the final model but did not exhibit a significant main 
effect and were excluded to retain the maximum degrees of freedom (the overall F statis tics for 
explanatory variables in additional models are shown in supplementary Table 2). Once the best fit 
model was identified, standardised residuals were extracted and plotted against fitted values to 
examine underlining assumption of normal distribution and heteroscedasticity. We also tested for an 
interaction between genotype and sex. All statistical tests are two-tailed, p<0.05. 
 
To ensure that the benchmark population reflected the demographic profile of our lab-based cohort, 
we could only use a sub-population of our global SHQ database. We developed a data extraction 
method using MATLAB (code, data, associated protocols, and materials available from authors on 
request) that allowed us to generate the population level database. This data was then pre-processed 
using the same normalisation procedure as detailed above. Linear mixed models examined the effects 
of sex and age on a population level benchmark. Finally, logistic regression was used to quantify how 
well SHQ variables such as distance travelled could classify APOE risk status using both the lab-
based sample and the benchmark population. ROC curves were used as measures of sensitivity and 
specificity of SHQ as opposed to standard memory tasks such as the ROCF test to detect preclinical 
AD. 
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Figure Legends 
Fig. 1. SHQ Goal-orientated Wayfinding levels (A) 6, (B) 8 and (C) 11. Players initially see a map 
featuring a start location and several checkpoints (in red) to find in a set order. Checkpoints are 
buoys with flags marking the checkpoint number. Participants study a map of the level for a  
recorded number of seconds. When participants exit the map view, they are asked to immediately 
find the checkpoints (or goals) in the order indicated on the map under timed conditions. As 
participants navigate the boat through the level, they must keep track of their location using 
selfmotion and environmental landscape cues such as water-land separation. The initiation time is 
zero as the boat accelerates immediately after the map disappears. If the participant takes more 
than a set time, an arrow appears pointing in the direction along the Euclidean line to the goal to aid 
                                 Cognitive diagnostics of ‘at risk’ Alzheimer’s disease 
                   
13 
 
navigation. (D) In flare accuracy levels (here level 9 and 14), participants are not provided with an 
allocentric map. Instead, they immediately navigated along a river to find a flare gun. Once they find 
the flare gun at the end of the river, the boat rotates by 180°, and participants are asked to choose 
one of three possible directions (right, front, left) that they believe points to the starting point. This 
level requires participants to i) form an accurate representation of the starting point relative to their  
position and ii) integrate this representation with a representation of the direction they are facing 
after the rotation. Depending on their accuracy, players receive either one, two or three stars. 
 
Fig. 2. Mixed effects models, with subject level random effects, adjusted for age, sex and baseline 
cognitive ability show A Main effect of genotype (b=0.22; p=0.004) on Wayfinding distance; e3e4 
carriers participants deviate from the more Euclidean trajectory leading to an overall greater  
distance travelled to complete the wayfinding levels relative to the e3e3 carriers. B No main effect of 
genotype on wayfinding duration (i.e. time taken to complete wayfinding levels); both groups used 
the same boat acceleration during wayfinding. C No main effect of genotype on flare accuracy which 
required participants to integrate newly acquired allocentric information with egocentric-viewpoint 
based cues presented at the end of the level. The spatial trajectory of each participant (colours red 
and green was used to differentiate the trajectories by the genetic groups) on wayfinding level 6 D 
level 8 E and level 11 F using x and y coordinates generated during gameplay. The maps generated 
illustrated a drift like navigation tendency in the e3e4 group that can be characterised as 
navigational preference to deviate from the most Euclidean path and travel toward the border of the 
environment compared to the e3e3 who demonstrated a preference to navigate more along the 
direct path to the checkpoint goal. A by level analysis on Wayfinding distance in the three levels 
showed that the e4 allele increased Wayfinding distance on level 6 (F=5.48, p=0.023) and level 8 
(F=4.08, p=0.04). 
 
Fig. 3. ROC curves for SHQ distance (pink line [lab-cohort]; dark pink line [lab – benchmark 
combined]) and non-verbal episodic memory (gold line [lab-cohort]) predicting APOE genotype. SHQ 
(lab-cohort) AUC .714, SE .068, 95% CI .555 - .822 | SHQ distance (lab – benchmark combined) AUC 
.701 SE .031 95% CI .639 - .759 | Non-verbal episodic memory (lab-cohort): AUC .541, SE .074, 95% 
CI .286 - .578. 
 
Fig. 4 Each e3e4 carrier score (red line) on SHQ distance plotted against the normal distribution of 
scores from an age-sex-education matched sub-population of the benchmark dataset (green 
histogram). Wayfinding distance scores are on the x axis and frequency of the benchmark population 
on the y axis. Sex is represented by M = male, F = female sex. Age is illustrated under each 
distribution right of sex. 
